Pediatric Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab

Am J Respir Crit Care Med. 2021 Mar 1;203(5):640-642. doi: 10.1164/rccm.202009-3489LE.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Anticardiolipin / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome / complications
  • Antiphospholipid Syndrome / drug therapy*
  • Antiphospholipid Syndrome / genetics
  • Antiphospholipid Syndrome / immunology
  • Blood Proteins / genetics
  • Brachiocephalic Veins / diagnostic imaging
  • Bronchiolitis, Viral / complications
  • Complement C3b Inactivator Proteins / genetics
  • Complement Inactivating Agents / therapeutic use*
  • Computed Tomography Angiography
  • Continuous Renal Replacement Therapy
  • Evoked Potentials, Visual
  • Humans
  • Infant
  • Intensive Care Units, Pediatric
  • Jugular Veins / diagnostic imaging
  • Male
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / therapy*
  • Plasma Exchange
  • Respiratory Syncytial Virus Infections / complications
  • Sequence Deletion
  • Sinus Thrombosis, Intracranial / diagnostic imaging
  • Sinus Thrombosis, Intracranial / etiology
  • Thrombocytopenia / blood
  • Thrombocytopenia / drug therapy
  • Thrombocytopenia / etiology
  • Thrombophilia / blood
  • Thrombophilia / etiology
  • Thrombophilia / therapy
  • Vasoconstrictor Agents / therapeutic use
  • Venous Thrombosis / diagnostic imaging
  • Venous Thrombosis / etiology
  • Water-Electrolyte Imbalance / etiology

Substances

  • Antibodies, Anticardiolipin
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Blood Proteins
  • CFHR1 protein, human
  • CFHR3 protein, human
  • Complement C3b Inactivator Proteins
  • Complement Inactivating Agents
  • Vasoconstrictor Agents
  • eculizumab